Robert Baird, RN, MSA, president of the National Cancer Treatment Alliance, discusses ways that employers of all sizes can pursue direct contracting with health care providers.
Robert Baird, RN, MSA, president of the National Cancer Treatment Alliance, discusses ways that employers of all sizes can pursue direct contracting with health care providers.
Transcript
Can employers pursue direct contracting arrangements even if they are not large? If so, how?
There are many different ways that employers can pursue a direct contracting strategy. You don't have to be a large employer. In fact, the self-insured and companies that are able to do direct contracting are becoming much smaller and have less employees. It used to be that you would have to have a few thousand employees, but the market has changed and there doesn't have to be one size fits all. I know employers can band together through chambers of commerce and other types of organizations that help them pull together. There's also the ability to contract with a national organization such as the National Cancer Treatment Alliance, and we can contract in areas where it's nationally, regionally, or locally.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More